Details of the Drug

General Information of Drug (ID: DMZAL7W)

Drug Name
Promazine
Synonyms
Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
Indication
Disease Entry ICD 11 Status REF
Psychomotor agitation MB23.M Approved [1]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 284.4
Topological Polar Surface Area (xlogp) 4.5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [3]
Elimination
2% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.9 hours [3]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 50.2258 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.11% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 8.1 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 333.33 mg/mL [2]
Chemical Identifiers
Formula
C17H20N2S
IUPAC Name
N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine
Canonical SMILES
CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
InChI
InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
InChIKey
ZGUGWUXLJSTTMA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4926
ChEBI ID
CHEBI:8459
CAS Number
58-40-2
DrugBank ID
DB00420
TTD ID
D00NAX
VARIDT ID
DR00887
INTEDE ID
DR1351

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Binder [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Promazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Promazine and Ivosidenib. Acute myeloid leukaemia [2A60] [52]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Promazine and Midostaurin. Acute myeloid leukaemia [2A60] [53]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Promazine and Daunorubicin. Acute myeloid leukaemia [2A60] [53]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Promazine and Arn-509. Acute myeloid leukaemia [2A60] [54]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Promazine and Gilteritinib. Acute myeloid leukaemia [2A60] [55]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Promazine and Oliceridine. Acute pain [MG31] [56]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Promazine and Scopolamine. Addictive disorder [6C50-6C5Z] [57]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Promazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [58]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Promazine and Memantine. Alzheimer disease [8A20] [57]
Galantamine DMEO794 Moderate Antagonize the effect of Promazine when combined with Galantamine. Alzheimer disease [8A20] [59]
Rivastigmine DMG629M Moderate Antagonize the effect of Promazine when combined with Rivastigmine. Alzheimer disease [8A20] [59]
Donepezil DMIYG7Z Moderate Antagonize the effect of Promazine when combined with Donepezil. Alzheimer disease [8A20] [59]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Promazine and Metronidazole. Amoebiasis [1A36] [60]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Promazine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [61]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Promazine and Ivabradine. Angina pectoris [BA40] [54]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Promazine and Dronedarone. Angina pectoris [BA40] [53]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Promazine and Amyl nitrite. Angina pectoris [BA40] [61]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Promazine and Nifedipine. Angina pectoris [BA40] [61]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Promazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [62]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Promazine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [57]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Promazine and Cilostazol. Arterial occlusive disease [BD40] [53]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Promazine and Posaconazole. Aspergillosis [1F20] [53]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Levalbuterol. Asthma [CA23] [63]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Terbutaline. Asthma [CA23] [64]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Promazine and Pirbuterol. Asthma [CA23] [63]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Salbutamol. Asthma [CA23] [63]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Formoterol. Asthma [CA23] [64]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Promazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [65]
Methylphenidate DM7SJD6 Moderate Antagonize the effect of Promazine when combined with Methylphenidate. Attention deficit hyperactivity disorder [6A05] [65]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Promazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [66]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Promazine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [53]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Promazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [53]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Promazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [53]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Promazine and Linezolid. Bacterial infection [1A00-1C4Z] [67]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Promazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [66]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Promazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [60]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Promazine and Telithromycin. Bacterial infection [1A00-1C4Z] [53]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Promazine and Retigabine. Behcet disease [4A62] [68]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Promazine and Cariprazine. Bipolar disorder [6A60] [57]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Promazine and Loperamide. Bowel habit change [ME05] [69]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Promazine and Eribulin. Breast cancer [2C60-2C6Y] [53]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Promazine and Tamoxifen. Breast cancer [2C60-2C6Y] [53]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Promazine and Toremifene. Breast cancer [2C60-2C6Y] [53]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Promazine and Sotalol. Cardiac arrhythmia [BC9Z] [53]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Promazine when combined with Acetylcholine. Cataract [9B10] [70]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Promazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [71]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Promazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [72]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [64]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [63]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Promazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [72]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Promazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [64]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Promazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [72]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [64]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Promazine and Dihydrocodeine. Chronic pain [MG30] [56]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Promazine and Oxaliplatin. Colorectal cancer [2B91] [53]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Isoproterenol. Conduction disorder [BC63] [63]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Promazine and Olopatadine. Conjunctiva disorder [9A60] [73]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Promazine and Halothane. Corneal disease [9A76-9A78] [53]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Promazine and Propofol. Corneal disease [9A76-9A78] [74]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Promazine and Sevoflurane. Corneal disease [9A76-9A78] [53]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Promazine and Alfentanil. Corneal disease [9A76-9A78] [75]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Promazine and Remifentanil. Corneal disease [9A76-9A78] [75]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Promazine and Clofazimine. Crohn disease [DD70] [76]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Promazine and Mifepristone. Cushing syndrome [5A70] [53]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Promazine and Pasireotide. Cushing syndrome [5A70] [53]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Promazine and Sertraline. Depression [6A70-6A7Z] [53]
Trimipramine DM1SC8M Moderate Increased plasma concentrations of Promazine and Trimipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [77]
Imipramine DM2NUH3 Moderate Increased plasma concentrations of Promazine and Imipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [77]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Promazine caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [78]
Nortriptyline DM4KDYJ Moderate Increased plasma concentrations of Promazine and Nortriptyline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [77]
Paroxetine DM5PVQE Moderate Decreased metabolism of Promazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [79]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Promazine and Selegiline. Depression [6A70-6A7Z] [67]
Duloxetine DM9BI7M Moderate Decreased metabolism of Promazine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [80]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Promazine and Isocarboxazid. Depression [6A70-6A7Z] [67]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Promazine and Escitalopram. Depression [6A70-6A7Z] [53]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Promazine and OPC-34712. Depression [6A70-6A7Z] [57]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Promazine and Phenelzine. Depression [6A70-6A7Z] [67]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Promazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [77]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Promazine and Trazodone. Depression [6A70-6A7Z] [81]
Amoxapine DMKITQE Moderate Increased plasma concentrations of Promazine and Amoxapine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [77]
Doxepin DMPI98T Moderate Increased plasma concentrations of Promazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [82]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Promazine and Maprotiline. Depression [6A70-6A7Z] [57]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Promazine and Esketamine. Depression [6A70-6A7Z] [60]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Promazine and Nitroglycerin. Diabetic foot ulcer [BD54] [61]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Promazine and Hyoscyamine. Digestive system disease [DE2Z] [57]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Promazine and Mepenzolate. Digestive system disease [DE2Z] [58]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Promazine and Oxybutynine. Discovery agent [N.A.] [57]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Promazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [83]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Promazine and Meclizine. Dizziness and giddiness [MB48] [57]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Promazine and Deutetrabenazine. Dystonic disorder [8A02] [84]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Promazine and Ingrezza. Dystonic disorder [8A02] [85]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Promazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [86]
Stiripentol DMMSDOY Moderate Decreased metabolism of Promazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Promazine and Guanabenz. Essential hypertension [BA00] [88]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Promazine and Ethacrynic acid. Essential hypertension [BA00] [88]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Promazine and Phenoxybenzamine. Essential hypertension [BA00] [61]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Promazine and Nicardipine. Essential hypertension [BA00] [61]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Promazine and Mecamylamine. Essential hypertension [BA00] [61]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Promazine and Nadolol. Essential hypertension [BA00] [61]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Promazine and Solifenacin. Functional bladder disorder [GC50] [53]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Promazine and Tolterodine. Functional bladder disorder [GC50] [57]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Promazine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Promazine and Pentamidine. Fungal infection [1F29-1F2F] [53]
Terbinafine DMI6HUW Moderate Decreased metabolism of Promazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [90]
Amphotericin B DMTAJQE Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Amphotericin B. Fungal infection [1F29-1F2F] [60]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Promazine and Phentolamine. Gangrene [MC85] [61]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Promazine and Propantheline. Gastric ulcer [DA60] [57]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Promazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [53]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Acetazolamide. Glaucoma [9C61] [60]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Promazine and Brimonidine. Glaucoma [9C61] [91]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Promazine when combined with Pilocarpine. Glaucoma [9C61] [70]
Spironolactone DM2AQ5N Moderate Additive hypotensive effects by the combination of Promazine and Spironolactone. Heart failure [BD10-BD1Z] [61]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Promazine and Prazosin. Heart failure [BD10-BD1Z] [61]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Promazine and Eplerenone. Heart failure [BD10-BD1Z] [61]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Promazine and Carvedilol. Heart failure [BD10-BD1Z] [61]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Chlorothiazide. Heart failure [BD10-BD1Z] [60]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Furosemide. Heart failure [BD10-BD1Z] [60]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Promazine and Amiloride. Heart failure [BD10-BD1Z] [61]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Bumetanide. Heart failure [BD10-BD1Z] [60]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [60]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Promazine and Procarbazine. Hodgkin lymphoma [2B30] [67]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Promazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [92]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Promazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [93]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Promazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [53]
Ritonavir DMU764S Moderate Decreased metabolism of Promazine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Promazine and Isosorbide mononitrate. Hydrocephalus [8D64] [61]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Promazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [60]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Promazine and Eprosartan. Hypertension [BA00-BA04] [61]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Promazine and Acebutolol. Hypertension [BA00-BA04] [61]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Promazine and Moexipril. Hypertension [BA00-BA04] [61]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Promazine and Bisoprolol. Hypertension [BA00-BA04] [61]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Promazine and Captopril. Hypertension [BA00-BA04] [61]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Promazine and Trandolapril. Hypertension [BA00-BA04] [61]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Promazine and Methyldopa. Hypertension [BA00-BA04] [61]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Promazine and Clonidine. Hypertension [BA00-BA04] [61]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Promazine and Losartan. Hypertension [BA00-BA04] [61]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Promazine and Nebivolol. Hypertension [BA00-BA04] [61]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Promazine and Levamlodipine. Hypertension [BA00-BA04] [61]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Promazine and Fosinopril. Hypertension [BA00-BA04] [61]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Promazine and Doxazosin. Hypertension [BA00-BA04] [61]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Promazine and Verapamil. Hypertension [BA00-BA04] [61]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Promazine and TAK-491. Hypertension [BA00-BA04] [61]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Promazine and Fenoldopam. Hypertension [BA00-BA04] [61]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Indapamide. Hypertension [BA00-BA04] [60]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Promazine and Benazepril. Hypertension [BA00-BA04] [61]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Promazine and Labetalol. Hypertension [BA00-BA04] [61]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Promazine and Diazoxide. Hypertension [BA00-BA04] [61]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Promazine and Enalapril. Hypertension [BA00-BA04] [61]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Promazine and Perindopril. Hypertension [BA00-BA04] [61]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Promazine and Felodipine. Hypertension [BA00-BA04] [61]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Promazine and Quinapril. Hypertension [BA00-BA04] [61]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Promazine and Telmisartan. Hypertension [BA00-BA04] [61]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Promazine and Irbesartan. Hypertension [BA00-BA04] [61]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Promazine and Hydralazine. Hypertension [BA00-BA04] [61]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Promazine and Lisinopril. Hypertension [BA00-BA04] [61]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [60]
Fludrocortisone DMUDIR8 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [60]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Promazine and ITI-007. Insomnia [7A00-7A0Z] [57]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Promazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [53]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Promazine and Clidinium. Irritable bowel syndrome [DD91] [57]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Promazine and Dicyclomine. Irritable bowel syndrome [DD91] [57]
Physostigmine DM2N0TO Moderate Antagonize the effect of Promazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [59]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Promazine and Crizotinib. Lung cancer [2C25] [95]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Promazine and Porfimer Sodium. Lung cancer [2C25] [96]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Promazine and Ceritinib. Lung cancer [2C25] [53]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Promazine and Osimertinib. Lung cancer [2C25] [97]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Promazine and Selpercatinib. Lung cancer [2C25] [98]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Promazine and Lumefantrine. Malaria [1F40-1F45] [60]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Promazine and Chloroquine. Malaria [1F40-1F45] [99]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Promazine and Hydroxychloroquine. Malaria [1F40-1F45] [99]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Promazine and Quinine. Malaria [1F40-1F45] [53]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Promazine and Primaquine. Malaria [1F40-1F45] [53]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Promazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [54]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Promazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [100]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Promazine and Vemurafenib. Melanoma [2C30] [53]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Promazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [101]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Promazine and Propranolol. Migraine [8A80] [61]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Promazine and Lasmiditan. Migraine [8A80] [102]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Promazine and Panobinostat. Multiple myeloma [2A83] [103]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Promazine and Thalidomide. Multiple myeloma [2A83] [54]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Promazine and Siponimod. Multiple sclerosis [8A40] [60]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Promazine and Fingolimod. Multiple sclerosis [8A40] [104]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Promazine and Ozanimod. Multiple sclerosis [8A40] [54]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Promazine and Methoxsalen. Mycosis fungoides [2B01] [60]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Promazine and Romidepsin. Mycosis fungoides [2B01] [68]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Promazine and Nilotinib. Myeloproliferative neoplasm [2A20] [53]
Imatinib DM7RJXL Moderate Decreased metabolism of Promazine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [105]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Promazine and Dasatinib. Myeloproliferative neoplasm [2A20] [106]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Promazine when combined with Dextroamphetamine. Narcolepsy [7A20] [65]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Promazine and Droperidol. Nausea/vomiting [MD90] [53]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Promazine and Dimenhydrinate. Nausea/vomiting [MD90] [57]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Promazine and Prochlorperazine. Nausea/vomiting [MD90] [57]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Promazine and Promethazine. Nausea/vomiting [MD90] [57]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Promazine and Metoclopramide. Nausea/vomiting [MD90] [107]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Promazine and Granisetron. Nausea/vomiting [MD90] [53]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Promazine and Ondansetron. Nausea/vomiting [MD90] [53]
Bupropion DM5PCS7 Major Decreased metabolism of Promazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [53]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Promazine and Entrectinib. Non-small cell lung cancer [2C25] [54]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Promazine when combined with Phendimetrazine. Obesity [5B80-5B81] [65]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Promazine when combined with Amfepramone. Obesity [5B80-5B81] [65]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Promazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [108]
Benzphetamine DMIJATC Moderate Antagonize the effect of Promazine when combined with Benzphetamine. Obesity [5B80-5B81] [65]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Metolazone. Oedema [MG29] [60]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Polythiazide. Oedema [MG29] [60]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Promazine and Lofexidine. Opioid use disorder [6C43] [53]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Promazine and Apraclonidine. Optic nerve disorder [9C40] [91]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Promazine and Rucaparib. Ovarian cancer [2C73] [53]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Promazine and Pentazocine. Pain [MG30-MG3Z] [75]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Promazine and Dextropropoxyphene. Pain [MG30-MG3Z] [109]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Promazine and Butorphanol. Pain [MG30-MG3Z] [75]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Promazine and Oxymorphone. Pain [MG30-MG3Z] [75]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Promazine and Levorphanol. Pain [MG30-MG3Z] [75]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Promazine and Flavoxate. Pain [MG30-MG3Z] [57]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Promazine and Nalbuphine. Pain [MG30-MG3Z] [75]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Promazine when combined with Methamphetamine. Pain [MG30-MG3Z] [110]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Promazine and Buprenorphine. Pain [MG30-MG3Z] [111]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Promazine and Hydrocodone. Pain [MG30-MG3Z] [75]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Promazine and Meperidine. Pain [MG30-MG3Z] [75]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Promazine and Oxycodone. Pain [MG30-MG3Z] [75]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Promazine and Triclabendazole. Parasitic worm infestation [1F90] [68]
Pergolide DM14MAE Moderate Antagonize the effect of Promazine when combined with Pergolide. Parkinsonism [8A00] [112]
Opicapone DM1BKA6 Moderate Antagonize the effect of Promazine when combined with Opicapone. Parkinsonism [8A00] [113]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Promazine and Rasagiline. Parkinsonism [8A00] [67]
Biperiden DME78OA Moderate Antagonize the effect of Promazine when combined with Biperiden. Parkinsonism [8A00] [114]
Entacapone DMLBVKQ Moderate Antagonize the effect of Promazine when combined with Entacapone. Parkinsonism [8A00] [112]
Levodopa DMN3E57 Moderate Additive hypotensive effects by the combination of Promazine and Levodopa. Parkinsonism [8A00] [112]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Promazine and Pimavanserin. Parkinsonism [8A00] [115]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Promazine when combined with Bromocriptine. Parkinsonism [8A00] [112]
Apomorphine DMX38HQ Moderate Antagonize the effect of Promazine when combined with Apomorphine. Parkinsonism [8A00] [116]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Promazine and Methylscopolamine. Peptic ulcer [DA61] [57]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Promazine and Famotidine. Peptic ulcer [DA61] [60]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Promazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [117]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Promazine and Lefamulin. Pneumonia [CA40] [52]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Hydrocortisone. Postoperative inflammation [1A00-CA43] [60]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Promazine and Degarelix. Prostate cancer [2C82] [54]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Promazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [118]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Promazine and Nilutamide. Prostate cancer [2C82] [54]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Promazine and Enzalutamide. Prostate cancer [2C82] [54]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Promazine and Flutamide. Prostate cancer [2C82] [54]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Promazine and Bicalutamide. Prostate cancer [2C82] [54]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Promazine and Terazosin. Prostate hyperplasia [GA90] [61]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Promazine and Tamsulosin. Prostate hyperplasia [GA90] [61]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Promazine and Silodosin. Prostate hyperplasia [GA90] [61]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Promazine and Verteporfin. Psoriasis [EA90] [54]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Promazine and Fluphenazine. Psychotic disorder [6A20-6A25] [57]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Promazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [119]
Neupro DMHEAB1 Moderate Antagonize the effect of Promazine when combined with Neupro. Restless legs syndrome [7A80] [112]
Celecoxib DM6LOQU Moderate Decreased metabolism of Promazine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [120]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Promazine and Cyproheptadine. Rheumatoid arthritis [FA20] [57]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Promazine and Quetiapine. Schizophrenia [6A20] [53]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Promazine and Mesoridazine. Schizophrenia [6A20] [60]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Promazine and Thioridazine. Schizophrenia [6A20] [121]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Promazine and Aripiprazole. Schizophrenia [6A20] [57]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Promazine and Iloperidone. Schizophrenia [6A20] [53]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Promazine and Paliperidone. Schizophrenia [6A20] [53]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Promazine and Haloperidol. Schizophrenia [6A20] [53]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Promazine and Molindone. Schizophrenia [6A20] [57]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Promazine and Chlorpromazine. Schizophrenia [6A20] [57]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Promazine and Thiothixene. Schizophrenia [6A20] [57]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Promazine and Trifluoperazine. Schizophrenia [6A20] [57]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Promazine and Risperidone. Schizophrenia [6A20] [57]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Promazine and Amisulpride. Schizophrenia [6A20] [122]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Promazine and Asenapine. Schizophrenia [6A20] [53]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Promazine and Pimozide. Schizophrenia [6A20] [54]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Promazine and Fentanyl. Sensation disturbance [MB40] [75]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Promazine and Vardenafil. Sexual dysfunction [HA00-HA01] [53]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Promazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [53]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Promazine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [53]
Cisplatin DMRHGI9 Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [60]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Promazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [53]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Promazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [53]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Promazine and Pitolisant. Somnolence [MG42] [53]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Promazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [53]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Promazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [53]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Promazine and Lenvatinib. Thyroid cancer [2D10] [53]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Promazine and Cabozantinib. Thyroid cancer [2D10] [54]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Promazine and Tizanidine. Tonus and reflex abnormality [MB47] [123]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Promazine and Tacrolimus. Transplant rejection [NE84] [53]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Promazine and Atropine. Unspecific substance harmful effect [NE6Z] [57]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Promazine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [57]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Promazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [57]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Promazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [57]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Promazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [58]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Promazine and Procainamide. Ventricular tachyarrhythmia [BC71] [53]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Promazine and Propafenone. Ventricular tachyarrhythmia [BC71] [53]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Promazine and Flecainide. Ventricular tachyarrhythmia [BC71] [53]
⏷ Show the Full List of 286 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
7 Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
8 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
18 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
19 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
20 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
21 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
22 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
23 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
24 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
25 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
26 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
27 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
28 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
29 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
30 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
31 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
32 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
33 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
34 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
35 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
36 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
37 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
38 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
39 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
40 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
41 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
42 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
43 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
44 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
45 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
46 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
48 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
49 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
50 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
52 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
53 Canadian Pharmacists Association.
54 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
56 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
57 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
58 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
59 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
60 Cerner Multum, Inc. "Australian Product Information.".
61 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
62 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
63 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
64 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
65 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
66 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
67 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
68 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
69 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
70 Multum Information Services, Inc. Expert Review Panel.
71 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
72 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
73 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
74 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
75 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
76 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
77 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
78 Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi AP "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications." Pharmacol Res 35 (1997): 335-9. [PMID: 9264051]
79 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
80 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
81 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
82 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
83 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
84 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
85 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
86 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
87 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
88 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
89 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
90 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
91 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
92 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
93 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
94 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
95 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
96 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
97 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
98 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
99 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
100 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
101 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
102 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
103 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
104 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
105 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
106 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
107 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
108 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
109 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
110 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
111 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
112 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
113 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
114 Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
115 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
116 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
117 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
118 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
119 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
120 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
121 El-Yousef MK, Manier DH "Tricyclic antidepressants and phenothiazines." JAMA 229 (1974): 1419. [PMID: 4152942]
122 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
123 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.